Neovasc is developing the Tiara for the treatment of severe MR, a condition that affects approximately four million patients in the U.S. alone. Currently, conventional surgical treatments are only appropriate for about 20% of these patients, leaving the majority of patients untreated.
The Tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart.
Tiara has been designed specifically to address each of the challenges listed below and meet the need for transcatheter replacement of the mitral valve, rather than being adapted from an aortic valve. Tiara implantation is achieved through a transapical approach and does not require any hemodynamic support.
Nkomo, V.T., et al., Lancet, 2006;368(9540):1005-1011
Mirabel, M., et al., Eur Heart J, 2007;28(11):1358-1365
Lamas GA: Circulation 1997;96:827-33
Grigioni F: Circulation 2001;103:1759-64
Ellis SGAm J Cardiol 2002;89:315-8
Sachin S. Goel: JACC 2014 Vol. 63, No. 2